Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced a conference call scheduled for November 9, 2020, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020, and provide company updates. Infinity is advancing its first-in-class immuno-oncology product candidate, eganelisib, which selectively inhibits PI3K-gamma and is being evaluated in various clinical studies. Investors can access the call via toll-free and international dial-in numbers or through a live webcast available on Infinity's website.
Infinity Pharmaceuticals (NASDAQ: INFI) announced that the FDA has granted Fast Track designation for eganelisib in combination with chemotherapy and a checkpoint inhibitor for treating inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). The company is currently enrolling patients in the Phase 2 MARIO-3 study, in collaboration with Roche/Genentech. This designation facilitates expedited drug development for serious conditions. Earlier in the year, Infinity received a similar designation for eganelisib in treating advanced urothelial cancer.